Avadel Pharmaceuticals plc Overview
Pro stress-test →Avadel Pharmaceuticals operates as a biopharmaceutical company focused on sleep medicine, with its lead product LUMRYZ, a formulation of sodium oxybate for treating cataplexy and excessive daytime sleepiness in narcolepsy patients. As of February 12, 2026, Avadel completed its acquisition by Alkermes, which adds LUMRYZ to Alkermes' commercial portfolio.
Strategic Profile
Pro stress-test →Since launching LUMRYZ in 2023, Avadel built and scaled a commercial organization that drove strong demand, with an estimated market of over 50,000 oxybate-eligible narcolepsy patients in the United States. Avadel's pipeline includes valiloxybate, an in-licensed salt-free, once-at-bedtime oxybate candidate in phase 1 clinical development.
Competitive Landscape
Pro stress-test →The acquisition accelerates Alkermes' entry into the sleep medicine market and positions the combined organization to develop a late-stage pipeline focused on central disorders of hypersomnolence. Alkermes brings established commercial infrastructure and neuroscience expertise to expand LUMRYZ adoption across multiple sleep disorders.
Industry Context
Avadel Pharmaceuticals plc operates in Biopharmaceutical / Sleep Medicine.
Key facts
Founded: 2015 · Headquarters: Dublin, Ireland